Healthspan

Healthspan is the period of a person's life spent free of significant chronic disease and functional impairment. It is the quantity most longevity research says it is trying to extend, and the one it measures least consistently. Unlike lifespan, which has a single unambiguous endpoint, healthspan requires a decision about what counts as ill health — and that decision changes the answer by years.

§Why the definition matters

Lifespan is settled by a death certificate. Healthspan requires drawing a line somewhere on a continuum of decline, and the plausible lines are far apart. A definition based on the first diagnosis of any chronic condition puts the end of healthspan in the fifties for most people in high-income countries, since hypertension and osteoarthritis are near-universal. A definition based on loss of independence puts it in the late seventies or eighties. A definition based on self-rated health tracks neither reliably.

This is not a pedantic problem. It determines whether a given intervention appears to extend healthspan, compress it, or leave it unchanged, and it makes results from different studies non-comparable. The same cohort can show a decade of difference depending on which operationalization the analyst chose.

Terminology

"Healthspan" has no agreed technical definition and no standard measurement instrument. Papers using the word should be read for how they operationalized it; the choice is usually buried in the methods section and usually drives the headline result.

§Measures in practice

Several formal constructs are used as stand-ins.

Healthy life expectancy (HALE) is the World Health Organization's measure: life expectancy adjusted downward by time lived with disability, weighted by severity, using disability weights from the Global Burden of Disease programme. It is a population statistic computed from life tables and prevalence data, generally by the Sullivan method, and cannot be applied to an individual.

Disability-free life expectancy (DFLE) is the simpler binary version — years expected before the onset of a defined disability — and is more sensitive to where the disability threshold is set.

Frailty indices count accumulated deficits across dozens of clinical and functional items and express them as a proportion. The cumulative-deficit approach of Rockwood and colleagues and the phenotypic definition of Fried and colleagues, based on weight loss, exhaustion, weakness, slowness and low activity, are the two dominant families.¹ Frailty indices predict mortality and hospitalization well and are among the most portable measures across species.

Intrinsic capacity, developed by the WHO for its integrated care framework, aggregates locomotion, vitality, cognition, psychological state and sensory function. It is designed to be measured in primary care rather than in a research cohort.

None of these measures healthspan directly. Each measures something correlated with it, and the correlations among them are imperfect.

§The healthspan–lifespan gap

Across countries, people spend the last stretch of life in impaired health, and that stretch has not shrunk as lifespan has grown. A 2024 analysis of WHO member-state data reported a mean gap between life expectancy and healthy life expectancy of roughly a decade, wider in women than in men, wider in high-income countries than in low-income ones, and largest in the United States.²

The direction of change matters more than the level. If added years of life arrive mainly as added years of disability, the gain is smaller than the mortality statistics suggest — the expansion-of-morbidity scenario. The opposing possibility, in which illness is pushed into a shorter interval before death, is the subject of Compression of morbidity, and the evidence for it in national data has been mixed at best.

Why the gap widens rather than closes

Reducing mortality from a disease is not the same as reducing its prevalence. Countries that have been most successful against cardiovascular disease and cancer have largely converted fatal events into survivable chronic conditions, which lengthens lifespan and prevalence together. A therapy that prevented the disease outright would move the two measures in opposite directions.

§Healthspan in animal research

The distinction between lifespan and healthspan is sharper in model organisms, where both can be measured on a practical timescale. Mouse studies use grip strength, rotarod performance, gait speed, treadmill endurance, cognitive tasks, and standardized frailty indices adapted from clinical scales.

The results are a caution against assuming the two move together. Work in Caenorhabditis elegans found that several long-lived mutants spend a greater proportion of life in a frail, low-function state than wild-type worms — lifespan extended, healthspan proportionally not.³ That revives the objection first raised against Cynthia Kenyon's long-lived insulin-signalling mutants, that an animal may be living longer by living less. Similar dissociations appear in mice for some interventions. Several established geroprotectors do appear to extend both: Caloric restriction and Rapamycin improve multiple functional measures in rodents alongside lifespan, and Senolytics were developed specifically around functional endpoints such as gait speed and cardiac function rather than survival curves.

Whether any of this transfers is unresolved. The human evidence for Metformin and the TAME trial and for NAD+ precursors addresses metabolic markers, not function; the trials of heat and cold exposure are short and mechanistic; the only intervention with strong human evidence for preserving function is physical activity.

§As an endpoint

Healthspan's ambiguity is a practical obstacle for the field. Regulators approve drugs against defined indications with measurable endpoints, and "extends healthspan" is neither. This is one reason the Geroscience hypothesis programme has concentrated on composite outcomes — the incidence of multiple age-related diseases in a single trial — rather than on healthspan as such, and why biomarker validation and clock-based measures attract disproportionate attention.

Prize competitions have taken the opposite approach by specifying function directly. XPRIZE Healthspan defines its target as the restoration of muscle, cognitive and immune function in older adults, measured against a person's own baseline, over a fixed treatment window. Specifying the domains in advance sidesteps the definitional argument at the cost of ignoring everything outside them.

The commercial market has adopted the word almost entirely without measurement. Longevity clinics and supplement vendors advertise healthspan extension on the basis of biological age readouts, which measure neither health nor span.

§Open problems

The central unresolved question is whether healthspan and lifespan are separable in humans at all, or whether extending one necessarily drags the other along. The Hallmarks of aging framework implies they should be coupled, since the same damage processes drive both mortality and dysfunction. The animal data show they can come apart. If they can come apart in humans, an intervention could produce more disability rather than less — a possibility that longevity research discusses less than it should.

A second problem is that healthspan cannot be measured prospectively in an individual. A person's healthspan is known only in retrospect, which makes it useless as a clinical decision variable and pushes practice back onto proxies: frailty scores, functional tests, and the inflammatory and regenerative markers that correlate with them. Whether any proxy is good enough to run a trial on is the question the field has to answer before it can claim to be extending healthspan at all.

§See also

• Compression of morbidity
• Maximum human lifespan
• Longevity escape velocity
• Geroscience hypothesis
• Aging biomarkers
• The longevity dividend
• XPRIZE Healthspan

§References